Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 19/20 | 0.64 |
| ▸ | NPM1 | P06748 | 10/20 | 0.58 |
| ▸ | INSR | P06213 | 6/20 | 0.58 |
| ▸ | JAK2 | O60674 | 2/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL520369 | 0.96 | ALK (0.67) | ALKNPM1INSRJAK2KCNH2 | |
| SCHEMBL520370 | 0.85 | ALK (0.67) | ALKNPM1INSRJAK2KCNH2 | |
| SCHEMBL519721 | 0.84 | ALK (0.73) | ALKNPM1INSRJAK2KCNH2 | |
| SCHEMBL520882 | 0.84 | ALK (0.76) | ALKNPM1INSRJAK2KCNH2 | |
| SCHEMBL521152 | 0.83 | ALK (0.64) | ALKNPM1INSRJAK2KCNH2 | |
| SCHEMBL520609 | 0.82 | ALK (0.63) | ALKNPM1INSRJAK2KCNH2 | |
| SCHEMBL519796 | 0.78 | ALK (1.00) | ALKNPM1INSRJAK2KCNH2 | |
| SCHEMBL521084 | 0.78 | ALK (0.66) | ALKNPM1INSRJAK2KCNH2 | |
| SCHEMBL520378 | 0.78 | ALK (1.00) | ALKNPM1INSRJAK2KCNH2 | |
| SCHEMBL520815 | 0.77 | ALK (0.69) | ALKNPM1INSRJAK2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | JAK2, ALK, ABL1 | ALK 2/4885NPM1 1309/4885INSR 1738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.